Benjamin Graham fit · Defensive deep-value investing
Is Esperion Therapeutics, Inc. (ESPR) a Benjamin Graham Stock?
Meets only 2/7 Graham criteria — likely overpriced or unstable.
4/100
FNot a fit
2/7 criteria passed
Benjamin Graham's Criteria, Applied to ESPR
P/E ≤ 15
key—
P/B ≤ 1.5
key0.0x
Current ratio ≥ 2
1.0x
Debt / Equity ≤ 1
0.0x
How ESPR Scores on Other Strategies
Live Financial Snapshot
Market cap
$626.17M
P/E (TTM)
-
ROIC (TTM)
26.87%
Gross margin
53.54%
Frequently Asked Questions
What is ESPR's Benjamin Graham fit score?
ESPR scores 4/100 on our Benjamin Graham fit engine — grade F. Meets only 2/7 Graham criteria — likely overpriced or unstable.
Does Benjamin Graham actually own ESPR?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends ESPR.
How often is this score updated?
ESPR's Benjamin Graham fit score is recomputed daily from the latest TTM financials.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Benjamin Graham personally owns or recommends ESPR.